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Background: Fragile X syndrome is caused by the loss of FMRP expression due to methylation of the FMR1
promoter. Treatment of fragile X syndrome patients’ lymphoblastoid cells with 5-azadeoxycytidine results in
demethylation of the promoter and reactivation of the gene. The aim of the study was to analyze if methotrexate,
an agent which also reduces DNA methylation but with less toxicity than 5-azadeoxycytidine, has therapeutic
potential in fragile X syndrome.
Methods: Fibroblasts of fragile X syndrome patients were treated with methotrexate in concentrations ranging from 1
to 4 μg/ml for up to 14 days. FMR1 and FMRP expression were analyzed by quantitative PCR and western blotting.
Results: FMR1 mRNA was detected and levels correlated positively with methotrexate concentrations and time of
treatment, but western blotting did not show detectable FMRP levels.
Conclusions: We show that it is possible to reactivate FMR1 transcription in fibroblasts of fragile X syndrome patients
by treatment with methotrexate. However, we were not able to show FMRP expression, possibly due to the reduced
translation efficacy caused by the triplet repeat extension. Unless FMR1 reactivation is more effective in vivo our results
indicate that methotrexate has no role in the treatment of fragile X syndrome.Background
Fragile X syndrome (FXS, OMIM #300624) is the most
common monogenic cause of mental retardation. It is
caused by the expansion of a polymorphic CGG triplet
repeat in the 5′-untranslated region (UTR) of the fragile
X mental retardation 1 (FMR1) gene located on the long
arm of the X-chromosome (Xq27.3) [1]. In the normal
population the repeat size is 6 to 55; individuals with a
repeat size of 55 to 200 are considered permutation car-
riers and in FXS patients repeats of >200 are found (full
mutation) [2,3]. The full mutation leads to the loss of a
DNA-methylation boundary 650 to 800 nucleotides up-
stream of the CGG repeat in the first exon of the FMR1
gene [4]. In healthy individuals this boundary protects* Correspondence: phuppke@med.uni-goettingen.de
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reproduction in any medium, provided the orthe unmethylated FMR1 promoter from spreading
methylation. In FXS the promoter is methylated, leading
to silencing of the FMR1 gene resulting in absence of
the fragile X mental retardation protein (FMRP) [5,6].
The hypothesis that the FXS phenotype is caused by the
loss of FMRP is supported by the description of FXS pa-
tients with point mutations in the FMR1 gene that lead
to the production of a nonfunctional protein [7,8]. Intri-
guingly, rare male individuals have been described who
carry a full mutation allele but have normal intelligence,
and, in these individuals, the FMR1 promoter has been
found unmethylated and FMRP expressed [9-12]. These
findings have stimulated experiments that aimed to re-
activate the FMR1 gene by inducing demethylation.
Chiurazzi et al. were able to show that in vitro treatment
of fragile X patients’ lymphoblastoid cells with 5-
azadeoxycytidine (5-azadC) leads to expression of FMR1
mRNA and FMRP [13]. The promoter of the FMR1 gene
was unmethylated after 5-azadC treatment [14]. Unfor-
tunately, 5-azacytidine, a cytosine analog that inhibits
DNA methyltransferases and was developed for cancerl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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tients not feasible [15]. Here we show that treatment
with methotrexate (MTX), an agent used for the long-
term treatment of patients with rheumatoid arthritis and
found to decrease cellular methylation including DNA
methylation, also results in FMR1 expression but no de-
tectable FMRP levels [16-18].
Methods
Cell culture and drug treatment
Human fibroblasts were purchased from the Coriell
Institute (Camden, New Jersey, USA) and maintained as
monolayer cultures in Dulbecco’s modified Eagle’s medi-
um (DMEM/low glucose, PAA Laboratories GmbH,
Pasching, Austria) supplemented with 5 to 10% fetal bo-
vine serum (Biochrom AG, Berlin, Germany) and 0.1%
L-glutamine (PAA Laboratories GmbH, Pasching, Austria).
Cells were incubated at 37°C in an atmosphere of 5% CO2.
Before treatment, cells were seeded at an initial equal con-
centration in a total volume of 10 ml per culture plate and
the amount of fetal bovine serum in the culture medium
was reduced to 5%. Cells were treated daily with 0.5 to
4 μg/ml methotrexate (Calbiochem, Billerica, MA, USA)
and 1 μg/ml 5-aza-2′-deoxycytidine (Sigma, Deisenberg,
Germany), respectively. All treatments were performed
in triplicate. During treatment, the culture medium was
changed every 48 hours. Control plates included FXS
patient fibroblasts without treatment, and fibroblasts
from a healthy male. After 4 to 14 days all cells were
harvested and RNA was isolated.
RNA extraction
Cell pellets for the extraction of RNA were prepared from
each treatment by trypsinization. Total RNA was isolated
using peqGOLD TriFast reagent (PEQLAB Biotechnologie
GMBH, Erlangen, Germany) and QIAamp™ DNA Kits
(QIAGEN, Hilden, Germany), as recommended by the
manufacturer. RNA concentrations were measured using
a UV spectrophotometer (Nano Drop ND-1000, Thermo
Fisher Scientific, Wilmington, DE, USA).
Reverse transcription PCR
For cDNA synthesis, 2 to 3 μg of total RNA were reverse
transcribed (RT) in a 20 μl volume using oligo(dT)15 prim-
ers and SuperScript™ III Reverse Transcriptase (Super-
Script™ III First-Strand Synthesis System, Invitrogen,
Karlsruhe, Germany) according to manufacturer’s recom-
mendation. Transcription amplification was performed
using the forward primer 5′ gctaaagtgaggatgataaag 3′ and
the reverse primer 5′ atccttatgtgccgcctctttgg 3′ producing
a 204-bp fragment. As internal control of amplification, ol-
igonucleotides GAPDH forward (5′ gagtcaacggatttggtcgt
3′) and GAPDH reverse (5′ gacaagcttcccgttctcag 3′) were
employed to amplify a specific 185-bp product of theGAPDH gene. Thirty PCR cycles (95°C, 30 seconds; 57°C,
30 seconds; and 72°C, 40 seconds) were done using
HotStar-Taq polymerase with Q-Solution (Qiagen, Hilden,
Germany). The amplification products were analyzed on
2% agarose gels supplemented with GelRed (Biotrend,
Cologne, Germany).
Quantitative real-time PCR
First strand cDNAs for quantitative real-time PCR (qRT-
PCR) of RNA generated from treated, untreated and
control fibroblasts were synthesized as described above.
Quantitative RT-PCR was performed using the iQ5 cy-
cler (BioRad Laboratories, Munich, Germany) and the
iQ SYBR Green Supermix kit (BioRad Laboratories,
Munich, Germany). All qRT-PCR reactions were
performed in triplicate. Annealing temperatures for the
genes were set to 57°C. Reaction specificity was con-
trolled by post-amplification melting curve analysis.
Relative expression rates of target gene transcripts were
calculated using the 2-(ΔΔCt) method.
Methylation analysis
Fibroblasts were treated for 7 days with either 1 μg/ml
5-aza-2′-deoxycytidine or MTX 2 μg/ml. Methylation sta-
tus of the FMR1 promoter was analyzed by bisulfite con-
version of unmethylated cytosines using the using EpiTect
Bisulfite Kit (Qiagen, Venlo, Netherlands). Oligonucleo-
tides were designed as described by Pascale et al. [19].
Western blot analysis
5azadC and MTX-treated and untreated human fibro-
blasts were washed with PBS. Then cells were lysed in
750 μl RIPA buffer (150 mM NaCl, 50 mM Tris–HCl
pH 7.5, 0.1% SDS, 0.5% sodium deoxycholate, 1% NP-40,
protease inhibitors) per 10-cm plate for 15 minutes at 4°C.
Lysates were clarified by centrifugation (18000×g, 20 mi-
nutes at 4°C). A total of 50 μg of protein lysate were sepa-
rated on 10% SDS-PAGE and transferred to nitrocellulose
membrane for 90 minutes with 2mA/cm2 using blotting
buffer (48 mM Tris–HCl, 39 mM glycine, 0.04% w/v SDS,
20% methanol). Membranes were blocked in PBST + 5%
defatted milk followed by overnight incubation at 4°C with
a monoclonal antibody against FMRP (Euromedex
Souffelweyersheim, Cedex, France). Incubation with ap-
propriate secondary HRP-labelled antibody was followed
by detection with Lumi-Light Western blotting substrate
(Roche, Mannheim, Germany).
Results
RNA was isolated from fibroblast cell lines from a male
FXS patient and a healthy male and used for cDNA syn-
thesis. With oligonucleotides binding in exon 4 and exon
6 of the FMR1 gene, a 204-bp fragment of FMR1 was
300 bp
200 bp
Figure 1 FMR1 transcription in fragile X syndrome (FXS) patient and control fibroblasts. cDNA was synthesized from FXS patient
fibroblasts and control fibroblasts followed by PCR. A total of 5 μl of PCR products for FMR1 and 3 μl of PCR products for GAPDH were analyzed

















Figure 2 Effect of methotrexate (MTX)-treatment time and dosage on restoration of FMR1 transcription. Patient fibroblasts were treated
with MTX and cDNAs were synthesized followed by PCRs. PCRs were analyzed on 2% agarose gels. The upper panels of each figure show analysis
of 5 μl FMR1-PCRs, the lower panels show analysis of 3 μl GAPDH-PCRs. a) Cells were treated 4 and 7 days with 0.5, 1, 2 and 4 μg MTX per ml
cell culture medium. b) Cells were treated 4, 5, 6 and 8 days with 1 and 2 μg MTX per ml cell culture medium.












Figure 3 Quantitative analysis of the methotrexate (MTX) effect on fragile X syndrome (FXS) patient fibroblasts. Patient fibroblasts were
treated with 2 μg MTX per ml culture medium for 7, 9, 12 and 14 days. cDNAs were synthesized and real-time PCRs were performed. The relative
FMR1-expression of the treated cells is illustrated. The light and the dark grey bars show the results of two separate experiments.







Figure 4 Western blot analysis after treatment with methotrexate
(MTX). Patient fibroblasts were treated with varying concentration of
MTX or 5-azadeoxycytidine (5-azadC) 1 μg/ml for 9 days. C = control
fibroblasts.
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in the patient’s cells (Figure 1).
Since previous work showed that treatment with 5-aza-
2′-deoxycytidine (5-azadC) could restore transcription
of the FMR1 gene [13], this substance was included as
positive control. The fibroblasts were treated with vary-
ing time spans and concentrations of MTX in the cul-
ture medium. The experiments showed that it is possible
to restore low levels of FMR1 expression in fibroblasts
of the FXS patient. The minimal time span was 4 days
(data not shown). The signal of the bands increased with
an increasing time span of the treatment and was stronger
when the medium contained 2 μg per ml MTX compared
to 1 and 0.5 μg/ml. Using 4 μg MTX/ml did not seems to
enhance the effect any further (Figure 2a and 2b).
To quantify the effect of MTX treatment on FMR1
gene transcription, we performed real-time PCRs. Cells
were treated for 7 to 14 days with 2 μg MTX per ml cell
culture medium (Figure 3). As seen in the previous ex-
periments, restoration of FMR1 expression increased
with the time of MTX exposure. Surprisingly there was
a steep rise in expression between day 12 and 14. The
experiment was repeated and again the result showed a
similar pattern.
Western blot was used to analyze FMR1 protein
(FMRP) expression. However, we were not able to show
reliably any FMRP expression in the patient’s cells
treated with either MTX or 5-aza-2′-deoxycytidine. In
the fibroblast of the healthy control a very robust signal
for FMRP was detected (Figure 4).Analysis of the methylation of the FMR1 promoter
after treatment with MTX did not demonstrate demethyl-
ation while it showed a variable degree of demethylation
after treatment with 5-aza-2′-deoxycytidine (Figure 5).
Discussion and conclusions
Currently several clinical studies addressing various as-
pects of FXS are underway (clinicaltrials.gov). Most of
these studies are based on the 'mGluR' theory formu-
lated in 2004 by Bear, Huber and Warren [20]. However,
FMRP is implicated in various aspects of activity
Figure 5 Analysis of cytosine methylation in the FMR1 promoter after treatment with 5-azadeoxycytidine (5-azadC). The arrows indicate
CpGs that were partially demethylated.
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interact with 4% of mRNAs in human fetal brain [21,22].
A therapy directed to downstream targets of FMRP is
therefore likely to correct only some of several aspects
of the FXS phenotype. Reactivation of the gene, on the
other hand, would offer a possibility to correct all as-
pects. Studies in unaffected males with a full mutation
who were found to have reduced FMRP levels indicate
that the reactivation does not need to be complete
[10,11]. Furthermore, the description of variable FXS
phenotypes within one family due to variable degrees of
methylation might indicate that the non-physiological
methylation of the FMR1 gene promoter is less stable
than in physiologically methylated promoters, possibly
facilitating reactivation without disturbing the methyla-
tion of other promoters [23]. Using 5-azadC it has been
shown that it is possible to reactivate the FMR1 gene by
demethylation of the promoter [13]. We aimed to find a
drug that reactivates the FMR1 gene but with less toxicity
than 5-azadC. DNA methylation is mediated by CpG
methyltransferases (DNMT1) using S-adenosylmethionine
(SAM) as a methyl group donor. Folate in the form of 5-
methyltetrahydrofolate is essential for the recycling of
SAM after the methylation reaction. Folate deficient diet
has been found to cause reduced DNA methylation in
humans [24,25]. Methotrexate (MTX) is a folate antagon-
ist that acts by inhibiting dihydrofolate reductase (DHFR),
an enzyme that catalyzes the conversion of dihydrofolate
to tetrahydrofolate. MTX is used in the long-term treat-
ment of rheumatoid arthritis in children and adults. It has
been described that treatment with MTX decreases cellu-
lar methylation [16-18]. We therefore decided to study
MTX as a potential drug for the reactivation of the FMR1
gene. Firstly we analyzed FMR1 mRNA expression in fi-
broblasts from a male FXS patient and from a healthy
control. As expected, we did not detect FMR1 mRNA in
the FXS patients’ fibroblasts. Next, we treated the fibro-
blasts with MTX and used 5-azadC treatment as a positive
control. We found that not only treatment with 5-azadC
but also treatment with MTX resulted in detectable FMR1
mRNA levels. The effect of the MTX treatment was posi-
tively correlated with the time of treatment and the dosage
of MTX. The results that we obtained from the 5-azadC
treatment on FMR1 mRNA levels were comparable to
those reported by Chiurazzi et al. [13]. However incontrast to them, when we used western blotting we were
not able to detect any FMRP, either in the 5-azadC-treated
cells or in the MTX-treated cells. Most likely, the protein
levels were too low for detection. It has been described in
a lymphoblastoid cell line as well as in a mouse model
with an unmethylated full mutation that the CGG repeat
itself causes mRNA translation to be 40% less efficient
[14,26]. The FMRP levels might therefore be very low. On
the other hand, our experiments might understate the ef-
fects of MTX in vivo because cells grown in culture have
been shown to have an excess of de novo methylation of
CpG islands [27,28]. In fact, we found that our reactivation
experiments were less efficient after the fibroblasts had
undergone more cell cycles (data not shown).
MTX affects cell metabolism in many ways. It reduces
the synthesis of thymidylates and purines as well as the
conversion of homocysteine to methionine. MTX treat-
ment thereby leads to impaired DNA and protein syn-
thesis as well as reduced methylation of DNA and
proteins. Consequently, at this point of time, we cannot
prove that the expression of FMR1 found after MTX
treatment is caused by reduced DNA methylation. In
fact DNA methylation after treatment with MTX was
not altered. Additionally, the lack of FMR1 protein ex-
pression might be caused by the overall reduced protein
synthesis. Further experiments directed at understanding
the mode of action of MTX in the FXS fibroblasts might
also help us to improve the outcome of MTX treatment.
Unfortunately, no mouse model is available for in vivo
testing because even in mice carrying very long CGG re-
peats no abnormal methylation occurs [26]. Another op-
portunity to study the effect of MTX in FXS would be
an individual with the comorbidity of FXS and rheuma-
toid arthritis receiving MTX. Studying FMR1 mRNA
and FMRP expression in lymphocytes of such an individ-
ual would help to clarify the potential of MTX in FXS.
An inquiry was sent to the German FXS support organi-
zation (www.frax.de), but no individual in Germany with
such comorbidity is currently known. However, due to the
high prevalence of FXS and rheumatoid arthritis, it is
likely that such an individual exists in another country.
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